The Global Next Generation Sequencing Market size was estimated at USD 6.37 billion in 2021 and is expected to hit around USD 24.48 billion by 2031, poised to grow at a compound annual growth rate (CAGR) of 16.1% from 2022 to 2031.

Global Next Generation Sequencing Market: Breakup by Region, 2022 & 2031

Source: Primary Research and Secondary Research Analysis

The research, production, distribution, and use of cutting-edge DNA and RNA sequencing technologies, as well as associated goods and services, are collectively referred to as the "Global Next Generation Sequencing (NGS) Market." The next generation of DNA and RNA sequencing, commonly referred to as high-throughput sequencing, makes it possible to analyse genetic material quickly and effectively. It has uses in many different industries, including agriculture, clinical diagnostics, drug discovery, and genomics research.

The Next Generation Sequencing (NGS) landscape is being shaped by a number of important factors in the current global market environment. First and foremost, sequencing technologies constantly strive to be faster and more precise. Manufacturers are always coming up with new technologies to provide platforms that can process larger volumes of genetic data with more accuracy, allowing researchers to delve deeper into challenging biological issues.

Additionally, the NGS market is seeing an increasing focus on clinical applications and personalised medicine. Patient care has been revolutionised by the ability of NGS to analyse individual genomes, which has paved the possibility for customised medical treatments and targeted therapies. The fusion of genetics and healthcare has sparked collaborations between sequencing businesses and healthcare organisations, accelerating the use of NGS in clinical settings.

Another important development is the democratisation of sequencing, which involves initiatives to make NGS more widely available and reasonably priced. Due to this, small, portable sequencers have become available, allowing researchers and healthcare workers to do sequencing in settings with limited resources.

Download Free Sample Report

Recent Developments:

The environment of genetic analysis and research has recently undergone rapid changes due to the Global Next Generation Sequencing (NGS) Market. The constant improvement of long-read sequencing technologies is one notable development. Longer DNA segments can now be read by sequencers made by companies like Oxford Nanopore and PacBio, enabling more precise genome assembly and thorough structural variation analysis.

A noteworthy trend is the incorporation of NGS in clinical diagnosis. Regulatory approvals for NGS-based assays to identify diverse genetic abnormalities, cancer mutations, and infectious diseases are increasing. This is revolutionising patient care and treatment approaches by improving the accuracy and early diagnosis of medical disorders.

Another significant breakthrough is the fusion of NGS with data analytics and artificial intelligence. Utilising cutting-edge machine learning techniques and bioinformatics tools, significant insights are being gleaned from the enormous datasets produced by NGS. This facilitates the discovery of novel biomarkers, the identification of disease-associated genetic variants, and the prediction of treatment responses.

Additionally, there is more cooperation between pharmaceutical businesses and sequencing companies in the NGS sector. Through the use of NGS data, our alliance intends to speed up the identification of new therapeutic targets and the evaluation of drug efficacy.

Market Segmentation:

Market Breakup: By Technology

• Illumina Sequencing
• Ion Torrent Sequencing
• Pacific Biosciences Sequencing
• Oxford Nanopore Sequencing

Market Breakup: By Application

• Genomics Research
• Clinical Diagnostics
• Drug Discovery
• Agriculture
• Forensic Analysis

Market Breakup: By Workflow

• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis

Market Breakup: By End-User

• Research Institutions
• Academic Laboratories
• Clinical Laboratories
• Pharmaceutical Companies
• Biotechnology Firms

Regional Analysis

The size and scope of the global Next Generation Sequencing industry vary by region and are important and expanding. Below is a quick summary of the industry's regional analysis:

North America: The United States in particular is a major centre for NGS innovation and uptake. Market expansion is fuelled by a strong research infrastructure, considerable investments in genomics research, and collaborations between academics and business. Due to regulatory permissions, clinical applications are advancing as NGS is integrated into personalised healthcare and diagnostics.

Europe: The continent has a significant presence in genetics research and medical care. Sequencing centres and cooperative networks are well-established in nations including the UK, Germany, and France. Applications of NGS include medication development, diagnostics, and research. Market expansion is facilitated by favourable regulatory rules for diagnostics, however data privacy laws have an impact on data sharing practises.

Asia-Pacific: Growing investments in genomes research and increased public awareness of the advantages of personalised medicine are driving the rapid adoption of NGS in this region. India, China, and Japan are notable participants. Population genomics, the study of diseases, and improvements in agriculture all make use of NGS. However, there are obstacles including inconsistent regulatory regimes and data sharing standards.

South America: In both scientific and clinical contexts, South America is gradually embracing NGS. Infrastructure and resource constraints are a problem, but partnerships and collaborations are helping technology spread. NGS is used in forensics, disease research, and investigations of biodiversity. Growth depends critically on regulatory harmonisation and investments in healthcare infrastructure.

Middle East & Africa: While still in its infancy, NGS adoption in these regions shows potential. Disease surveillance, epidemiology, and understanding genetic variation are the main areas of focus. Growth may be hampered by a lack of funds for research and healthcare facilities. Advancements are being driven by partnerships with international organisations and capacity building programmes.

Market Breakup By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The Next Generation Sequencing Industry competitive landscape provides details by competitor. Details included are company outline, company financials, revenue generated, market potential, investment in research and development, new market initiatives, worldwide occurrence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The overhead data points providing are only related to the businesses’ focus related to Next Generation Sequencing marketplace.

Major players operating in the Global Next Generation Sequencing Industry are:

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies Ltd.
• Agilent Technologies Inc.
• Roche Holding AG
• Qiagen N.V.
• BGI Group
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Eurofins Scientific SE
• Beijing Genomics Institute
• Genewiz
• ArcherDX

Frequently Asked Questions (FAQs)

Q1) What is meant by Next Generation Sequencing?

Ans: Next Generation Sequencing (NGS) is advanced DNA/RNA analysis allowing rapid, high-throughput genetic data generation, revolutionizing research, diagnostics, and genomics applications.

Q2) Which was the dominant region for the Global Next Generation Sequencing Market in 2022?

Ans: North America was the dominant region for the global next generation sequencing market in 2022, with a market share of 49.25%. This is attributable to the presence of major clinical laboratories that are using next-generation sequencing technology to perform genetic tests. Additionally, the region has a strong healthcare infrastructure and a high level of R&D investment, which are also driving the growth of the market.

Q3) What are the challenges in the Global Next Generation Sequencing Market?

Ans: Data analysis complexity, cost, standardization, data privacy, regulatory hurdles, and addressing variant interpretation in clinical settings are some of the challenges of Global Next Generation Sequencing Market.

Q4) What are the major drivers for the Global Next Generation Sequencing Market?

Ans: Personalized medicine demand, decreasing sequencing costs, clinical applications expansion, research advancements, and agricultural/genomic discoveries are the drivers of Global Next Generation Sequencing Market.